Compass Therapeutics/$CMPX
1D1W1MYTD1Y5YMAX
Capital at risk
About Compass Therapeutics
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
- Ticker
- $CMPX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 39
- Headquarters
- Boston, United States
- Website
- www.compasstherapeutics.com
CMPX Metrics
BasicAdvanced
$360M
-
-$0.40
0.82
-
Price and volume
Market cap
$360M
Beta
0.82
52-week high
$6.88
52-week low
$1.61
Average daily volume
3.1M
Financial strength
Current ratio
11.216
Quick ratio
11.153
Long term debt to equity
4.815
Total debt to equity
5.801
Profitability
EBITDA (TTM)
-81.013
Management effectiveness
Return on assets (TTM)
-33.03%
Return on equity (TTM)
-56.66%
Valuation
Price to book
2.17
Price to tangible book (TTM)
2.17
Price to free cash flow (TTM)
-6.452
Free cash flow yield (TTM)
-15.50%
Free cash flow per share (TTM)
-0.31
Growth
Earnings per share change (TTM)
-10.17%
3-year earnings per share growth (CAGR)
3.74%
What the Analysts think about CMPX
Analyst ratings (Buy, Hold, Sell) for Compass Therapeutics stock.
Analyst projections of the future price of Compass Therapeutics stock.
Bulls say / Bears say
In May 2026, tovecimig plus paclitaxel achieved a 17.1% overall response rate versus 5.3% for paclitaxel alone and extended median progression-free survival to 4.7 months from 2.6 months (HR 0.44; p < 0.0001) in a Phase 2/3 biliary tract cancer study, underscoring robust clinical efficacy (Reuters)
The FDA granted Orphan Drug Designation for tovecimig in April 2026 and Compass intends to meet with the agency ahead of a planned BLA filing later this year, potentially expediting review and securing market exclusivity (Reuters)
As of March 31, 2026, Compass reported $195 million in cash and marketable securities, providing funding into 2028 and reducing the likelihood of near-term equity dilution (Reuters)
Compass reported a net loss of $66.5 million for 2025, reflecting substantial operating losses without any approved product revenue (Reuters)
Research and development expenses jumped 32% in 2025 due to higher manufacturing costs for tovecimig and CTX-10726, intensifying cash burn concerns (Reuters)
The Phase 2/3 COMPANION-002 study did not meet its overall survival secondary endpoint, with analyses confounded by a 54% crossover rate and failing to reach statistical significance, creating regulatory uncertainty ahead of a potential BLA submission (SEC.gov)
Data summarised monthly by Lightyear AI. Last updated on 19 Aug 2026.
CMPX Financial Performance
Revenues and expenses
CMPX Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing CMPX
AllEURUSDGBP
Fund name | Fund size | $CMPX weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
iShares MSCI World Small Cap$WSML | $9B | 0.00% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.00% |
iShares MSCI World Small Cap£WLDS | £6.7B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.